cisplatin,nivolumab
bms
['nivolumab', 'cisplatin', 'urothelial', 'cm 274', 'check,mate,274', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nct02632409', 'nivo']
cm 274 trial: with extended follow-up (median follow-up of 36.1 months), nivo continued to show dfs, nutrfs, and dmfs benefits versus pbo. in the pd-l1 1% pt, median dfs with nivo reached 52.6 months (8.4 m in the pbo arm). for pd-l1 -ve and no nac we need os results. #gu23 
Jefe de Servicio de Oncología Médica. Hospital Universitario Lucus Augusti, HULA. Grupo de Investigación Oncológica Traslacional, GIOT HULA. Cuenta personal